Type 2 Diabetes
Metabolic 5 original drugsMetabolic indication. Type 2 Diabetes has 5 FDA-approved novel treatments, led by SANOFI-AVENTIS US, with 292 active industry clinical trials across 22 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Type 2 Diabetes Market Leaders
Companies with the most FDA-approved novel Type 2 Diabetes drugs.
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q4 2026
HDM1002 200 mg
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Estimated · aging NCT07193459
Q4 2026
Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Estimated · aging NCT07033585
Q4 2026
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
CSPC Ouyi Pharmaceutical Co., Ltd.
Estimated · fresh NCT07026968
Q4 2026
CMG190303(Dapagliflozin/Rosuvastatin)
CMG Pharmaceutical Co. Ltd
Estimated · fresh NCT06772168
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Type 2 Diabetes Treatments by Mechanism
Top 12 mechanisms across 350 industry trials with a known mechanism of action.
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
29 trials 6 active 2 sponsors
GLP-1 Receptor Agonist
107 trials 3 active 3 sponsors
Insulin Analog
67 trials 4 sponsors
SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose
45 trials 2 sponsors
Dipeptidyl Peptidase 4 Inhibitor
37 trials 3 sponsors
Sodium-Glucose Cotransporter 2 Inhibitor
24 trials 5 sponsors
SGLT2
10 trials 4 sponsors
DPP-4
9 trials 2 sponsors
Anti-anginal
7 trials 1 sponsor
Sulfonylurea
6 trials 4 sponsors
DPP-4/SGLT2
6 trials 1 sponsor
HMG-CoA Reductase Inhibitor
3 trials 3 sponsors
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Type 2 Diabetes Clinical Pipeline by Phase
1923 industry-sponsored trials across 277 sponsors
Showing 100 of 237 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Novo Nordisk | Insulin icodec | — | RECRUITING | 2026-08-04 | NCT07112339 |
| Sanofi | iGlarLixi (insulin glargine/lixisenatide) | — | RECRUITING | 2026-09-18 | NCT06671587 |
| Boryung Pharmaceutical Co., Ltd | Metformin | — | RECRUITING | 2026-10-01 | NCT06972732 |
| JW Pharmaceutical | Empagliflozin/Metformin | — | RECRUITING | 2027-03-31 | NCT07442006 |
| Sequence LifeScience, Inc. | — | — | RECRUITING | 2027-07 | NCT07086443 |
| Applied Biologics, LLC | — | — | RECRUITING | 2027-08 | NCT07159282 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2027-10 | NCT07438444 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Metformin | — | RECRUITING | 2027-12-31 | NCT07244003 |
| DexCom, Inc. | — | — | ACTIVE NOT RECRUITING | 2026-11-02 | NCT07603284 |
| Sanofi | iGlarLixi (insulin glargine/lixisenatide) | — | ACTIVE NOT RECRUITING | 2026-06-26 | NCT06716424 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2025-10-21 | NCT05433584 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | ganagliflozin | — | NOT YET RECRUITING | 2031-10-30 | NCT07116928 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | COMPLETED | 2026-04-15 | NCT06635057 |
| Eli Lilly | Insulin Lispro-aabc | Insulin Analog [EPC] | COMPLETED | 2025-09-02 | NCT06370715 |
| Bayer | Finerenone (Kerendia, BAY94-8862) | — | COMPLETED | 2025-07-03 | NCT05705271 |
| AstraZeneca | Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets | — | COMPLETED | 2025-06-30 | NCT06327815 |
| Novo Nordisk | semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2025-06-18 | NCT05035082 |
| Corcept Therapeutics | Mifepristone 300 MG [Korlym] | — | COMPLETED | 2024-11-19 | NCT05772169 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | COMPLETED | 2024-07-15 | NCT05564039 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2024-01-18 | NCT05533632 |
| Eli Lilly | Dulaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2024-01-16 | NCT05659537 |
| Celltrion Pharm, Inc. | Pioglitazone + Alogliptin | — | COMPLETED | 2024-01-02 | NCT03499704 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | COMPLETED | 2023-10-31 | NCT05706506 |
| Emerald Clinical Inc. | Dapagliflozin 10 MG [Farxiga] | — | COMPLETED | 2023-05-30 | NCT04620590 |
| Sanofi | Insulin glargine/Lixisenatide | — | COMPLETED | 2023-03-28 | NCT05114590 |
| AstraZeneca | dapagliflozin and saxagliptin | — | COMPLETED | 2023-03-14 | NCT04445714 |
| Sanofi | Insulin glargine 300 U/ml | — | COMPLETED | 2023-02-24 | NCT05002933 |
| Sanofi | Insulin glargine (U300) | — | COMPLETED | 2022-12-23 | NCT04980027 |
| Yuhan Corporation | pregabalin sustained release tablet | — | COMPLETED | 2022-12-20 | NCT05624853 |
| Getz Pharma | Insulin | — | COMPLETED | 2022-11-30 | NCT05161741 |
| Boehringer Ingelheim | Empagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2022-08-19 | NCT04531462 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2022-06-09 | NCT03596450 |
| Getz Pharma | Metformin / Sitagliptin Oral Tablet | — | COMPLETED | 2022-04-28 | NCT05167513 |
| Getz Pharma | Empagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2021-08-10 | NCT05359432 |
| Eli Lilly | Insulin Glargine | Insulin Analog [EPC] | COMPLETED | 2021-07-30 | NCT04153981 |
| Mannkind Corporation | — | — | COMPLETED | 2021-05-28 | NCT04849845 |
| Sanofi | Alogliptin | — | COMPLETED | 2020-12-14 | NCT03794336 |
| Sanofi | INSULIN GLARGINE (U300) | — | COMPLETED | 2020-09-23 | NCT03760991 |
| JW Pharmaceutical | Anagliptin BID Treatment | — | COMPLETED | 2020-09-02 | NCT04810507 |
| Yuhan Corporation | Rosuvamibe | — | COMPLETED | 2020-08-12 | NCT03597412 |
| Sanofi | INSULIN GLARGINE (HOE901) | — | COMPLETED | 2020-06-29 | NCT03359837 |
| Profil Institut für Stoffwechselforschung GmbH | Empagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2020-04-20 | NCT03254849 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2020-01-29 | NCT04189848 |
| Novo Nordisk | Insulin degludec | Insulin Analog [EPC] | COMPLETED | 2019-12-20 | NCT03687827 |
| Handok Inc. | Teneligliptin | — | COMPLETED | 2019-12-12 | NCT03508323 |
| AstraZeneca | Dapagliflozin | SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose | COMPLETED | 2019-11-04 | NCT03338855 |
| Daiichi Sankyo | High-dose colesevelam | — | COMPLETED | 2019-11-01 | NCT01258075 |
| AstraZeneca | Saxagliptin | — | COMPLETED | 2019-08-23 | NCT02917031 |
| Novo Nordisk | liraglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2019-08-05 | NCT02730377 |
| Eli Lilly | Dulaglutide Pen | — | COMPLETED | 2019-04-12 | NCT03724981 |
| Novartis | vildagliptin | — | COMPLETED | 2019-04-04 | NCT01528254 |
| Laboratoires Teriak | Clopidogrel | — | COMPLETED | 2019-03-24 | NCT03329261 |
| Yuhan Corporation | Rosuvamibe® Tab | — | COMPLETED | 2019-03-05 | NCT03446261 |
| Fresenius Kabi | Lactulose crystals 20 g | — | COMPLETED | 2019-03-05 | NCT03666546 |
| Eli Lilly | Insulin Analog Mid Mixture | — | COMPLETED | 2019-02-19 | NCT03018938 |
| Johnson & Johnson | Canagliflozin 300 mg | — | COMPLETED | 2018-10-01 | NCT03267576 |
| Merck | Omarigliptin | — | COMPLETED | 2018-08-21 | NCT02906709 |
| LG Chem | Gemigliptin 50mg | — | COMPLETED | 2018-07-13 | NCT03202563 |
| Eli Lilly | Dulaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-06-18 | NCT02750410 |
| Eisai Inc. | Lorcaserin hydrochloride | — | COMPLETED | 2018-05-14 | NCT02019264 |
| Sanofi | INSULIN GLARGINE | Insulin Analog [EPC] | COMPLETED | 2018-04-26 | NCT02836704 |
| Sanofi | INSULIN GLARGINE | Insulin Analog [EPC] | COMPLETED | 2018-04-20 | NCT02545842 |
| Sanofi | Irbesartan/atorvastatin fixed dose combination | — | COMPLETED | 2018-04-19 | NCT02842359 |
| Orient Europharma Co., Ltd. | Mitiglinide | — | COMPLETED | 2018-04 | NCT04349696 |
| Sanofi | Insulin glargine, 300 U/ml | — | COMPLETED | 2018-03-02 | NCT02451137 |
| Eli Lilly | Dulaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2018-02-28 | NCT03315780 |
| Takeda | Trelagliptin | — | COMPLETED | 2018-02-09 | NCT03231709 |
| Boehringer Ingelheim | Linagliptin | Dipeptidyl Peptidase 4 Inhibitor [EPC] | COMPLETED | 2018-01-18 | NCT01897532 |
| AstraZeneca | Dapagliflozin | SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose | COMPLETED | 2018-01-15 | NCT02564926 |
| Sanofi | INSULIN GLARGINE (U300) | — | COMPLETED | 2017-12-22 | NCT02954692 |
| Novo Nordisk | — | — | COMPLETED | 2017-12-09 | NCT02617693 |
| Sanofi | INSULIN GLARGINE | Insulin Analog [EPC] | COMPLETED | 2017-11-27 | NCT02606357 |
| Astellas | Ipragliflozin | — | COMPLETED | 2017-11-09 | NCT02847091 |
| Takeda | Trelagliptin | — | COMPLETED | 2017-10-21 | NCT03014479 |
| Sanofi | insulin glargine (U300) | — | COMPLETED | 2017-10-20 | NCT02967211 |
| Sanofi | insulin glargine (U300) | — | COMPLETED | 2017-10-16 | NCT02967224 |
| Chemical Resources | Fenfuro | — | COMPLETED | 2017-10 | NCT03066089 |
| Sanofi | Insulin glargine, 300U/mL | — | COMPLETED | 2017-08-15 | NCT02738151 |
| Sanofi | Lixisenatide (AVE0010) | — | COMPLETED | 2017-08-04 | NCT02941367 |
| Sanofi | insulin glargine (U300) | — | COMPLETED | 2017-07-24 | NCT02967237 |
| Kowa Company, Ltd. | Tofogliflozin | — | COMPLETED | 2017-07 | NCT02537834 |
| Boehringer Ingelheim | empagliflozin 10mg | — | COMPLETED | 2017-06-02 | NCT02589626 |
| Takeda | Trelagliptin | — | COMPLETED | 2017-04-27 | NCT02771093 |
| Boehringer Ingelheim | Empagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2017-04-18 | NCT02589639 |
| Boehringer Ingelheim | linagliptin | Dipeptidyl Peptidase 4 Inhibitor [EPC] | COMPLETED | 2017-04-18 | NCT02240680 |
| Novartis | — | — | COMPLETED | 2017-04-06 | NCT02670928 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2017-03-18 | NCT02582242 |
| AstraZeneca | Dapagliflozin | SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose | COMPLETED | 2017-03-13 | NCT02471404 |
| Johnson & Johnson | Canagliflozin, 100 mg | — | COMPLETED | 2017-02-23 | NCT01989754 |
| AstraZeneca | Bydureon | — | COMPLETED | 2016-12-07 | NCT02533453 |
| Takeda | Azilsartan Medoxomil | — | COMPLETED | 2016-11-15 | NCT02517866 |
| Handok Inc. | Teneligliptin | — | COMPLETED | 2016-09-26 | NCT02512523 |
| Novo Nordisk | biphasic insulin aspart 30 | — | COMPLETED | 2016-09-20 | NCT02453685 |
| Astellas | Ipragliflozin | — | COMPLETED | 2016-07-07 | NCT02291874 |
| Bristol-Myers Squibb | Metformin XR | — | COMPLETED | 2016-06-01 | NCT01864174 |
| Takeda | Metformin | — | COMPLETED | 2016-06-01 | NCT02049814 |
| Dexa Medica Group | DLBS1033 | — | COMPLETED | 2016-06 | NCT01865474 |
| AstraZeneca | Dapagliflozin | SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose | COMPLETED | 2016-04-28 | NCT02426541 |
| Tanabe Pharma Corporation | Canagliflozin (TA-7284) | — | COMPLETED | 2016-04 | NCT02622113 |
| Takeda | Azilsartan | — | COMPLETED | 2016-04 | NCT02079805 |
Showing 100 of 696 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| BrightGene Bio-Medical Technology Co., Ltd. | BGM0504 | — | RECRUITING | 2026-07-31 | NCT07064486 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1002 200 mg | — | RECRUITING | 2026-10-10 | NCT07193459 |
| CMG Pharmaceutical Co. Ltd | CMG190303(Dapagliflozin/Rosuvastatin) | — | RECRUITING | 2026-11-04 | NCT06772168 |
| Celltrion | Metformin | — | RECRUITING | 2026-12 | NCT07093476 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 | — | RECRUITING | 2027-02 | NCT07060456 |
| Hudson Biotech | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2027-02-14 | NCT07481747 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1002 100 mg | — | RECRUITING | 2027-02-16 | NCT07082114 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 1 | — | RECRUITING | 2027-08-28 | NCT07394114 |
| Pfizer | PF-08653944 | — | RECRUITING | 2027-10-12 | NCT07400653 |
| Hanmi Pharmaceutical Company Limited | HM11260C | — | RECRUITING | 2027-11 | NCT07379333 |
| Eli Lilly | Dulaglutide | GLP-1 Receptor Agonist [EPC] | RECRUITING | 2027-12 | NCT06739122 |
| Novo Nordisk | Cagrisema | — | RECRUITING | 2028-02-23 | NCT07564414 |
| NewAmsterdam Pharma | obicetrapib 10 mg + ezetimibe 10 mg FDC daily | — | RECRUITING | 2028-03 | NCT07219602 |
| Roche | — | — | RECRUITING | 2028-03-12 | NCT07670416 |
| Roche | — | — | RECRUITING | 2028-08-07 | NCT07351058 |
| Prokidney | Renal Autologous Cell Therapy (REACT/ rilparencel) | — | RECRUITING | 2029-12 | NCT05099770 |
| Boehringer Ingelheim | Vicadrostat | — | RECRUITING | 2029-12-14 | NCT07064473 |
| EMS | MADALENA ASSOCIATION | — | RECRUITING | 2026-07 | NCT04670666 |
| THPharm Corp. | THP-00101 | — | RECRUITING | 2026-06-01 | NCT06647745 |
| BrightGene Bio-Medical Technology Co., Ltd. | Drug: 5 mg BGM0504 Administered SC | — | RECRUITING | 2026-03-20 | NCT06716216 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 tablet | — | RECRUITING | 2026-02-18 | NCT06589765 |
| BrightGene Bio-Medical Technology Co., Ltd. | Drug: 5 mg BGM0504 Administered SC | — | RECRUITING | 2025-12-29 | NCT06716203 |
| Boryung Pharmaceutical Co., Ltd | BR1019A | — | RECRUITING | 2025-04 | NCT06220773 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2026-08 | NCT06260722 |
| Gan & Lee Pharmaceuticals. | GZR18 | — | ACTIVE NOT RECRUITING | 2026-08-07 | NCT06777238 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 Injection | — | ACTIVE NOT RECRUITING | 2026-09-30 | NCT06649344 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2026-10 | NCT06297603 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes | — | ACTIVE NOT RECRUITING | 2026-10-18 | NCT07033585 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR | — | ACTIVE NOT RECRUITING | 2026-10-30 | NCT07026968 |
| Gan & Lee Pharmaceuticals. | GZR18 | — | ACTIVE NOT RECRUITING | 2026-12-11 | NCT06778967 |
| Amgen | Maridebart cafraglutide | — | ACTIVE NOT RECRUITING | 2027-01-21 | NCT06858878 |
| Novo Nordisk | Cagrilintide | — | ACTIVE NOT RECRUITING | 2027-05-12 | NCT07220759 |
| Eli Lilly | Orforglipron | — | ACTIVE NOT RECRUITING | 2027-08 | NCT06993792 |
| Eli Lilly | Orforglipron | — | ACTIVE NOT RECRUITING | 2027-08 | NCT06972472 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2027-11-07 | NCT03811561 |
| Novo Nordisk | Oral semaglutide | — | ACTIVE NOT RECRUITING | 2026-06-29 | NCT07271251 |
| Novo Nordisk | Cagrilintide | — | ACTIVE NOT RECRUITING | 2026-06-02 | NCT06534411 |
| Beijing Dongfang Biotech Co., Ltd. | Exendin-4 Fc fusion protein injection | — | ACTIVE NOT RECRUITING | 2026-05-01 | NCT06254014 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2026-05 | NCT05929079 |
| Dong-A ST Co., Ltd. | DA5221-T1 | — | ACTIVE NOT RECRUITING | 2025-09-05 | NCT06290349 |
| Jiangsu HengRui Medicine Co., Ltd. | Noiiglutide Injection | — | ACTIVE NOT RECRUITING | 2025-05-28 | NCT06649773 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 Injection | — | ACTIVE NOT RECRUITING | 2025-05-14 | NCT06650007 |
| Qilu Pharmaceutical Co., Ltd. | QLG1091 | — | NOT YET RECRUITING | 2026-12 | NCT07487103 |
| Guangdong Raynovent Biotech Co., Ltd | RAY1225 | — | NOT YET RECRUITING | 2026-12-01 | NCT07139535 |
| Guangdong Raynovent Biotech Co., Ltd | RAY1225 | — | NOT YET RECRUITING | 2026-12-01 | NCT07139548 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20094 Injection | — | NOT YET RECRUITING | 2027-03-30 | NCT07156500 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20094 Injection | — | NOT YET RECRUITING | 2027-03-30 | NCT07156539 |
| Gan & Lee Pharmaceuticals. | GZR33 Injection | — | NOT YET RECRUITING | 2027-04-10 | NCT07527078 |
| Oramed, Ltd. | ORMD-0801 8 mg | — | NOT YET RECRUITING | 2027-04-25 | NCT06731075 |
| Eli Lilly | Orforglipron | — | NOT YET RECRUITING | 2027-05 | NCT07613307 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 1 | — | NOT YET RECRUITING | 2027-08-30 | NCT07417306 |
| The United Bio-Technology (Hengqin) Co., Ltd. | UBT251 Injection 2.0 mg | — | NOT YET RECRUITING | 2027-09-24 | NCT07659574 |
| Carnot Laboratories | Bofanglutide | — | NOT YET RECRUITING | 2027-10 | NCT07628985 |
| Daewoong Pharmaceutical Co. LTD. | DWP16001 | — | NOT YET RECRUITING | 2027-11 | NCT07619833 |
| The United Bio-Technology (Hengqin) Co., Ltd. | UBT251 Injection 2.0 mg group | — | NOT YET RECRUITING | 2028-02-29 | NCT07653477 |
| AstraZeneca | Elecoglipron | — | NOT YET RECRUITING | 2028-05-23 | NCT07664553 |
| AstraZeneca | Elecoglipron | — | NOT YET RECRUITING | 2028-05-23 | NCT07662213 |
| AstraZeneca | Elecoglipron | — | NOT YET RECRUITING | 2028-07-05 | NCT07662109 |
| AstraZeneca | Elecoglipron | — | NOT YET RECRUITING | 2028-07-13 | NCT07662135 |
| AstraZeneca | Elecoglipron | — | NOT YET RECRUITING | 2028-07-14 | NCT07662044 |
| Shandong New Time Pharmaceutical Co., LTD | F027 | — | NOT YET RECRUITING | 2028-08-01 | NCT07046273 |
| Novo Nordisk | NNC0487-0111 | — | NOT YET RECRUITING | 2028-12-12 | NCT07400107 |
| Novo Nordisk | CagriSema (Cagrilintide B and Semaglutide I) | — | NOT YET RECRUITING | 2029-09-07 | NCT07282613 |
| Eli Lilly | Orforglipron | — | NOT YET RECRUITING | 2030-03 | NCT07668336 |
| EMS | LID104 | — | NOT YET RECRUITING | 2026-05 | NCT05886088 |
| Tonghua Dongbao Pharmaceutical Co.,Ltd | Insulin Degludec/liraglutide Injection | — | NOT YET RECRUITING | 2025-10 | NCT06559722 |
| Celltrion | CT-L03 Group 1 | — | COMPLETED | 2026-04-16 | NCT06571591 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2026-03-16 | NCT05803421 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2026-03-04 | NCT06221969 |
| CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | TG103 | — | COMPLETED | 2026-02-03 | NCT06235086 |
| CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | TG103 | — | COMPLETED | 2026-01-23 | NCT06258148 |
| Boehringer Ingelheim | — | — | COMPLETED | 2025-12-12 | NCT06066528 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2025-11-19 | NCT06065540 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 tablet | — | COMPLETED | 2025-11-13 | NCT06672172 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2025-10-01 | NCT06323174 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2025-09-26 | NCT06192108 |
| Jiangsu HengRui Medicine Co., Ltd. | HR17031 injection | — | COMPLETED | 2025-09-19 | NCT06881264 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | COMPLETED | 2025-09-17 | NCT06184568 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2025-09-15 | NCT06109311 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2025-09-09 | NCT06323161 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2025-08-22 | NCT06045221 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2025-08-08 | NCT05872620 |
| HighTide Biopharma Pty Ltd | HTD1801 | — | COMPLETED | 2025-06-13 | NCT06415773 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | COMPLETED | 2025-06-12 | NCT04255433 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2025-06-05 | NCT06010004 |
| Novo Nordisk | IcoSema | — | COMPLETED | 2025-05-27 | NCT06269107 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | semaglutide injection (HD1916) | — | COMPLETED | 2025-05-14 | NCT06161844 |
| Jiangsu HengRui Medicine Co., Ltd. | HR17031 injection | — | COMPLETED | 2025-05-13 | NCT06871761 |
| Novo Nordisk | Oral semaglutide | — | COMPLETED | 2025-04-29 | NCT04596631 |
| Novo Nordisk | Insulin Icodec | — | COMPLETED | 2025-04-14 | NCT05813912 |
| Merck | Ertugliflozin 5 mg | — | COMPLETED | 2025-04-11 | NCT04029480 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2025-04-03 | NCT05971940 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2025-03-05 | NCT05514535 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2025-01-28 | NCT05394519 |
| HighTide Biopharma Pty Ltd | HTD1801 | — | COMPLETED | 2024-12-12 | NCT06350890 |
| HighTide Biopharma Pty Ltd | HTD1801 | — | COMPLETED | 2024-12-12 | NCT06353347 |
| Tonghua Dongbao Pharmaceutical Co.,Ltd | THDB0206 Injection | — | COMPLETED | 2024-12-10 | NCT05834868 |
| Jiangsu HengRui Medicine Co., Ltd. | INS068 injection | — | COMPLETED | 2024-11-23 | NCT05699408 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2024-11-21 | NCT04865770 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2024-10-28 | NCT05649137 |
Showing 100 of 365 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Housey Healthcare ULC | HP-211 | — | RECRUITING | 2026-10 | NCT07546929 |
| Arrowhead Pharmaceuticals | ARO-ALK7 | — | RECRUITING | 2026-10 | NCT06937203 |
| Eli Lilly | LY3938577 | — | RECRUITING | 2026-11 | NCT07215312 |
| Eli Lilly | LY3457263 | — | RECRUITING | 2026-12 | NCT06897475 |
| Eli Lilly | Macupatide | — | RECRUITING | 2027-03 | NCT07215559 |
| Alnylam Pharmaceuticals | ALN-4324 | — | RECRUITING | 2027-05-28 | NCT07465224 |
| Biomea Fusion Inc. | icovamenib 100mg | — | RECRUITING | 2027-06 | NCT07502495 |
| Biomea Fusion Inc. | icovamenib 100 mg | — | RECRUITING | 2027-06 | NCT07502508 |
| Alnylam Pharmaceuticals | ALN-4324 | — | RECRUITING | 2027-08-31 | NCT06845202 |
| Hanmi Pharmaceutical Company Limited | HM15275 | — | RECRUITING | 2027-09 | NCT07527650 |
| Novo Nordisk | NNC0662-0419 | — | RECRUITING | 2027-09-03 | NCT07415954 |
| Sparrow Pharmaceuticals | clofutriben | — | RECRUITING | 2027-12-31 | NCT07296484 |
| Estar Medical dba Medical Technologies, LTD | — | — | RECRUITING | 2026-05-15 | NCT06810726 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 1 | — | RECRUITING | 2026-01-31 | NCT07109700 |
| Mankind Pharma Limited | MKP10241 | — | RECRUITING | 2026-01-19 | NCT07098663 |
| Hyundai Pharm | HD-6277 100mg | — | RECRUITING | 2025-03-31 | NCT06647550 |
| Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | Fuling Yunhua Granules | — | RECRUITING | 2025-01-30 | NCT06575478 |
| Gan and Lee Pharmaceuticals, USA | GZR101 Injection | — | RECRUITING | 2024-12 | NCT06558708 |
| Golo | — | — | RECRUITING | 2024-11 | NCT05844644 |
| Ascletis Pharma (China) Co., Limited | ASC30 tablets | — | ACTIVE NOT RECRUITING | 2026-08 | NCT07321678 |
| Zealand Pharma | Petrelintide | — | ACTIVE NOT RECRUITING | 2026-08-13 | NCT06926842 |
| Novo Nordisk | CagriSema (Cagrilintide B and Semaglutide I) | — | ACTIVE NOT RECRUITING | 2026-08-21 | NCT06797869 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-09 | NCT05536804 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Aleniglipron | — | ACTIVE NOT RECRUITING | 2026-09 | NCT07400588 |
| Roche | RO7795081 | — | ACTIVE NOT RECRUITING | 2026-11-27 | NCT07112872 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-3167 Injection | — | ACTIVE NOT RECRUITING | 2026-12 | NCT07472725 |
| MediciNova | MN-001 | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT05464784 |
| Gan & Lee Pharmaceuticals. | GZR102 | — | ACTIVE NOT RECRUITING | 2026-06-28 | NCT07055386 |
| HiDO Technologies | — | — | ACTIVE NOT RECRUITING | 2026-05-31 | NCT06691256 |
| Carmot Therapeutics, Inc. | Enicepatide | — | ACTIVE NOT RECRUITING | 2026-05-29 | NCT06628362 |
| NodThera Limited | NT-0796 | — | ACTIVE NOT RECRUITING | 2026-05-21 | NCT07055516 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-3167 | — | ACTIVE NOT RECRUITING | 2026-02 | NCT07018453 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-01-08 | NCT06037252 |
| Guangdong Raynovent Biotech Co., Ltd | RAY1225 | — | ACTIVE NOT RECRUITING | 2025-12-20 | NCT06254274 |
| Amgen | Maridebart Cafraglutide | — | ACTIVE NOT RECRUITING | 2025-10-06 | NCT06660173 |
| Gan & Lee Pharmaceuticals. | GZR101-80 | — | NOT YET RECRUITING | 2027-02-11 | NCT07387003 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 Tablet | — | NOT YET RECRUITING | 2027-05 | NCT07599410 |
| Novo Nordisk | CagriSema | — | NOT YET RECRUITING | 2027-08-25 | NCT07357740 |
| Novo Nordisk | UBT251 | — | NOT YET RECRUITING | 2027-10-04 | NCT07668388 |
| Global Institute of Stem Cell Therapy and Research | DT2-SCT intravenous infusion | — | NOT YET RECRUITING | 2028-06 | NCT06789302 |
| ARKAY Therapeutics | Metformin | — | NOT YET RECRUITING | 2028-11-26 | NCT03686657 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-3167 | — | COMPLETED | 2026-04-22 | NCT06688123 |
| Pfizer | MET097 Injection | — | COMPLETED | 2025-12-29 | NCT06897202 |
| AstraZeneca | AZD5004 | — | COMPLETED | 2025-12-19 | NCT06579105 |
| The United Bio-Technology (Hengqin) Co., Ltd. | Semaglutide Injection (Ozempic®) | — | COMPLETED | 2025-11-21 | NCT07163624 |
| Novo Nordisk | NNC0487-0111 subcutanous | — | COMPLETED | 2025-10-01 | NCT06542874 |
| Eli Lilly | Retatrutide | — | COMPLETED | 2025-10-01 | NCT05936151 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2025-09-24 | NCT06131372 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2025-09-19 | NCT06326047 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 | — | COMPLETED | 2025-07-15 | NCT06415214 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1002 50 mg | — | COMPLETED | 2025-05-30 | NCT06481085 |
| Prokidney | Renal Autologous Cell Therapy (REACT) | — | COMPLETED | 2025-05-20 | NCT05018416 |
| HighTide Biopharma Pty Ltd | HTD1801 | — | COMPLETED | 2025-04-30 | NCT05623189 |
| Bayer | Finerenone (BAY94-8862 ) 10 mg | — | COMPLETED | 2025-03-14 | NCT05254002 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20094 | — | COMPLETED | 2025-03-07 | NCT06901648 |
| Dongguan HEC Biopharmaceutical R&D Co., Ltd. | HEC88473, Placebo, Dulaglutide | — | COMPLETED | 2025-02-27 | NCT06148649 |
| Biomea Fusion Inc. | BMF-219 | — | COMPLETED | 2024-11-18 | NCT05731544 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 | — | COMPLETED | 2024-11-15 | NCT06393348 |
| Amgen | Maridebart Cafraglutide | — | COMPLETED | 2024-10-08 | NCT05669599 |
| Haisco Pharmaceutical Group Co., Ltd. | HSK7653 10 mg | — | COMPLETED | 2024-10-05 | NCT06703268 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 injection | — | COMPLETED | 2024-09-24 | NCT05966272 |
| BrightGene Bio-Medical Technology Co., Ltd. | BGM0504 Administered SC | — | COMPLETED | 2024-08-13 | NCT06974825 |
| Imbria Pharmaceuticals, Inc. | IMB-1018972 | — | COMPLETED | 2024-08-06 | NCT04826159 |
| Beijing QL Biopharmaceutical Co.,Ltd | ZT002 Injection | — | COMPLETED | 2024-07-22 | NCT07065032 |
| Gan and Lee Pharmaceuticals, USA | GZR4 Injection | — | COMPLETED | 2024-07-13 | NCT06202079 |
| Gan and Lee Pharmaceuticals, USA | GZR101 | — | COMPLETED | 2024-06-28 | NCT06199505 |
| Inventiva Pharma | IVA337 | — | COMPLETED | 2024-03-30 | NCT05232071 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20094 5mg | — | COMPLETED | 2024-01-04 | NCT06118008 |
| Prokidney | Renal Autologous Cell Therapy (REACT) | — | COMPLETED | 2023-12 | NCT02836574 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2023-10-12 | NCT05486065 |
| Gan and Lee Pharmaceuticals, USA | GZR18 | — | COMPLETED | 2023-09-28 | NCT06256523 |
| Hyundai Pharm | HD-6277 | — | COMPLETED | 2023-06-28 | NCT05666128 |
| Glyscend, Inc. | GLY-200 | — | COMPLETED | 2023-03-14 | NCT05478525 |
| Carmot Therapeutics, Inc. | CT-868 | — | COMPLETED | 2023-02-28 | NCT05110846 |
| Novo Nordisk | NNC0480-0389 | — | COMPLETED | 2023-02-13 | NCT05144984 |
| HighTide Biopharma Pty Ltd | HTD1801 | — | COMPLETED | 2023-01-17 | NCT06411275 |
| Prokidney | Renal Autologous Cell Therapy (REACT) | — | COMPLETED | 2022-11-17 | NCT03270956 |
| Eli Lilly | LY3502970 | — | COMPLETED | 2022-09-30 | NCT05048719 |
| Eli Lilly | LY3437943 | — | COMPLETED | 2022-07-08 | NCT04867785 |
| Novo Nordisk | Semaglutide 2.4 mg | — | COMPLETED | 2022-07-07 | NCT04982575 |
| Oramed, Ltd. | ORMD-0801 (Insulin) capsule 8 mg BD | — | COMPLETED | 2022-06-27 | NCT04618744 |
| Oramed, Ltd. | ORMD-0801 | — | COMPLETED | 2022-06-07 | NCT04564846 |
| Jiangsu HengRui Medicine Co., Ltd. | INS068 injection | — | COMPLETED | 2022-05-28 | NCT04663282 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | COMPLETED | 2022-04-28 | NCT04965506 |
| AstraZeneca | Cotadutide 100 micrograms | — | COMPLETED | 2022-03-08 | NCT04515849 |
| Bayer | Finerenone (Kerendia, BAY94-8862) | — | COMPLETED | 2021-12-31 | NCT05013008 |
| Boehringer Ingelheim | BI 456906 | — | COMPLETED | 2021-10-08 | NCT04153929 |
| Eli Lilly | LY3209590 | — | COMPLETED | 2021-10-08 | NCT04450394 |
| Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SY-004 | — | COMPLETED | 2021-07-09 | NCT04217291 |
| AstraZeneca | AZD9567 | — | COMPLETED | 2021-06-09 | NCT04556760 |
| Pfizer | PF-06882961 | — | COMPLETED | 2021-06-08 | NCT03985293 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | COMPLETED | 2021-05-28 | NCT04466904 |
| MedImmune LLC | MEDI0382 | — | COMPLETED | 2021-04-14 | NCT03555994 |
| Neuraly, Inc. | NLY01 | — | COMPLETED | 2020-12-04 | NCT04159766 |
| Roger New | Oral insulin | — | COMPLETED | 2020-07-11 | NCT06473662 |
| Jiangsu HengRui Medicine Co., Ltd. | HS-20004 | — | COMPLETED | 2020-06-04 | NCT03848793 |
| Eli Lilly | LY3209590 | — | COMPLETED | 2020-02-18 | NCT03736785 |
| HighTide Biopharma Pty Ltd | HTD1801 | — | COMPLETED | 2020-02-07 | NCT03656744 |
| Novo Nordisk | Semaglutide (administered by DV3396 pen) | — | COMPLETED | 2020-01-04 | NCT04143945 |
| Pila Pharma | XEN-D0501 | — | COMPLETED | 2019-12-19 | NCT05353686 |
Showing 100 of 625 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Hua Medicine Limited | HMS1005 | — | RECRUITING | 2026-08-13 | NCT07568678 |
| Merck | MK-1403 + additive coformulation | — | RECRUITING | 2026-08-28 | NCT07242469 |
| Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | MS-553 | — | RECRUITING | 2026-10-30 | NCT04187443 |
| Eli Lilly | LY4057996 SC | — | RECRUITING | 2026-12 | NCT06945406 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-3167 Injection | — | RECRUITING | 2027-03 | NCT07032688 |
| Alveus Therapeutics, Inc. | ALV-100 | — | RECRUITING | 2027-04 | NCT07399678 |
| Novo Nordisk | NNC9733-0001 | — | RECRUITING | 2027-08-30 | NCT07270731 |
| Amgen | AMG 127 | — | RECRUITING | 2027-10-02 | NCT07590193 |
| Regend Therapeutics | REGEND003 | — | RECRUITING | 2027-12 | NCT07275788 |
| Novo Nordisk | NNC1679-0001 | — | RECRUITING | 2028-06-25 | NCT07570992 |
| Vincentage Pharma Co., Ltd | CX11 (VCT220) | — | RECRUITING | 2026-06-30 | NCT07349381 |
| Gan and Lee Pharmaceuticals, USA | GZR4 injection | — | RECRUITING | 2026-04-01 | NCT07146347 |
| OrsoBio, Inc | TLC-6740 Oral Solution | — | RECRUITING | 2026-02 | NCT05822544 |
| 1Globe Health Institute | QX1206 | — | RECRUITING | 2025-07 | NCT06694935 |
| Neurotronic, Inc. | — | — | RECRUITING | 2025-01 | NCT05369065 |
| Neurotronic, Inc. | — | — | RECRUITING | 2025-01 | NCT05363761 |
| Hyundai Pharm | Empagliflozin 25 MG | — | RECRUITING | 2024-09-02 | NCT06578676 |
| AdipoPharma LLC | PATAS Trifluoroacetate | — | ACTIVE NOT RECRUITING | 2026-07-30 | NCT07223333 |
| Eli Lilly | LY4086940 | — | ACTIVE NOT RECRUITING | 2026-08 | NCT06945419 |
| Eli Lilly | Dulaglutide | GLP-1 Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-08 | NCT07313813 |
| Roche | RO7204239 | — | ACTIVE NOT RECRUITING | 2026-09-13 | NCT07137585 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-11 | NCT07299084 |
| Amgen | Maridebart cafraglutide | — | ACTIVE NOT RECRUITING | 2026-11-15 | NCT07160257 |
| Celltrion | L03RD1 | — | ACTIVE NOT RECRUITING | 2026-05-24 | NCT07533539 |
| Eilean Therapeutics | ZE63-0302 | — | ACTIVE NOT RECRUITING | 2026-04-21 | NCT07234864 |
| Gan and Lee Pharmaceuticals, USA | GZR18 | — | ACTIVE NOT RECRUITING | 2024-12-09 | NCT06554054 |
| Gan & Lee Pharmaceuticals. | GZR4 injection A | — | NOT YET RECRUITING | 2026-07-29 | NCT07670897 |
| Nimble Science Ltd. | — | — | NOT YET RECRUITING | 2026-08 | NCT06704022 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 tablets | — | NOT YET RECRUITING | 2026-09 | NCT06506175 |
| The United Bio-Technology (Hengqin) Co., Ltd. | UBT38006 | — | NOT YET RECRUITING | 2026-10-25 | NCT07630233 |
| Chipscreen Biosciences, Ltd. | Chiglitazar/Metformin extended-release tablets under fasting conditions | — | NOT YET RECRUITING | 2026-10-26 | NCT07511010 |
| Daewoong Pharmaceutical Co. LTD. | DWRX5003 | — | NOT YET RECRUITING | 2026-04-30 | NCT07539415 |
| Gan & Lee Pharmaceuticals. | GZR102 injection | — | NOT YET RECRUITING | 2025-09-30 | NCT06974487 |
| Gan and Lee Pharmaceuticals, USA | GZR18 and metformin | — | NOT YET RECRUITING | 2025-03-19 | NCT06670209 |
| Bostal Drug Delivery Co., Ltd | Semaglutide Extended-release for Injectable Suspension, 1 mg | — | NOT YET RECRUITING | 2024-11 | NCT06422624 |
| Chong Kun Dang Pharmaceutical | CKD-383(Fed) | — | NOT YET RECRUITING | 2024-08-01 | NCT06492655 |
| Merck | MK-2828 | — | COMPLETED | 2026-05-04 | NCT07089784 |
| Eli Lilly | Retatrutide | — | COMPLETED | 2026-05-04 | NCT06982846 |
| Eli Lilly | LY3549492 | — | COMPLETED | 2026-03-02 | NCT06869018 |
| Novo Nordisk | NNC0471-0119 H | — | COMPLETED | 2026-02-22 | NCT07068295 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2026-01-28 | NCT07004322 |
| Eli Lilly | LY3549492 | — | COMPLETED | 2026-01-27 | NCT07073170 |
| Eli Lilly | LY3209590 | — | COMPLETED | 2026-01-02 | NCT06362265 |
| Humanis Saglık Anonim Sirketi | Empagliflozin / Metformin HCl XR Tablets | — | COMPLETED | 2025-12-29 | NCT07372118 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2025-12-28 | NCT06403761 |
| BrightGene Bio-Medical Technology Co., Ltd. | BGM0504 | — | COMPLETED | 2025-12-25 | NCT06929156 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2025-12-10 | NCT06567041 |
| Eccogene | AZD5004 | — | COMPLETED | 2025-11-28 | NCT06988553 |
| Chong Kun Dang Pharmaceutical | CKD-383 0.25/12.5/1000mg | — | COMPLETED | 2025-11-09 | NCT07304726 |
| Chong Kun Dang Pharmaceutical | CKD-383 0.5/10/1000mg | — | COMPLETED | 2025-11-07 | NCT07304700 |
| Carmot Australia First Pty Ltd | CT-996 | — | COMPLETED | 2025-11-07 | NCT05814107 |
| Chong Kun Dang Pharmaceutical | CKD-383 0.5/25/1000mg | — | COMPLETED | 2025-11-03 | NCT07304687 |
| Celltrion | L03RD1 | — | COMPLETED | 2025-10-03 | NCT07158346 |
| Humanis Saglık Anonim Sirketi | Empagliflozin / Metformin HCl XR Tablets | — | COMPLETED | 2025-09-24 | NCT07266766 |
| Humanis Saglık Anonim Sirketi | Empagliflozin/Linagliptin/Metformin HCL | — | COMPLETED | 2025-09-15 | NCT07213895 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2025-09-10 | NCT06513104 |
| Humanis Saglık Anonim Sirketi | Ertugliflozin/Metformin film coated tablets | — | COMPLETED | 2025-09-04 | NCT07266779 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 | — | COMPLETED | 2025-09-02 | NCT06246175 |
| Nanexa AB | NEX-22A, a prolonged release formulation of liraglutide | — | COMPLETED | 2025-07-18 | NCT06439056 |
| Novo Nordisk | Semaglutide B | — | COMPLETED | 2025-07-10 | NCT06642584 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | [14C]HRS9531 | — | COMPLETED | 2025-06-17 | NCT06855147 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | Acetaminophen | Nonsteroidal Anti-inflammatory Drug [EPC] | COMPLETED | 2025-06-09 | NCT06723691 |
| Humanis Saglık Anonim Sirketi | Empagliflozin + Linagliptin filmcoated tablets | — | COMPLETED | 2025-05-14 | NCT07039890 |
| Shandong Suncadia Medicine Co., Ltd. | [14C]HRS-7535 | — | COMPLETED | 2025-04-16 | NCT06819488 |
| Pfizer | Rosuvastatin | — | COMPLETED | 2025-04-11 | NCT06279234 |
| AstraZeneca | AZD5004(Part A) | — | COMPLETED | 2025-03-13 | NCT06703658 |
| Novo Nordisk | Insulin icodec | — | COMPLETED | 2025-03-10 | NCT06288412 |
| Humanis Saglık Anonim Sirketi | Empagliflozin + Linagliptin film-coated tablets | — | COMPLETED | 2025-03-07 | NCT06932159 |
| Novo Nordisk | NNC0487-0111 | — | COMPLETED | 2025-02-24 | NCT06559527 |
| Boryung Pharmaceutical Co., Ltd | BR3409 | — | COMPLETED | 2025-01-26 | NCT06879158 |
| Boryung Pharmaceutical Co., Ltd | BR3006 | — | COMPLETED | 2025-01-12 | NCT06890299 |
| Boryung Pharmaceutical Co., Ltd | BR3006 | — | COMPLETED | 2025-01-03 | NCT06890286 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 injection | — | COMPLETED | 2024-12-26 | NCT06654960 |
| Boryung Pharmaceutical Co., Ltd | BR1019 | — | COMPLETED | 2024-12-11 | NCT06636877 |
| Chong Kun Dang Pharmaceutical | CKD-383 | — | COMPLETED | 2024-12-08 | NCT06695598 |
| Chong Kun Dang Pharmaceutical | CKD-383 | — | COMPLETED | 2024-12-07 | NCT06695572 |
| Chong Kun Dang Pharmaceutical | CKD-378 25/1000mg | — | COMPLETED | 2024-12-07 | NCT06709807 |
| Boryung Pharmaceutical Co., Ltd | BR3409 | — | COMPLETED | 2024-12-07 | NCT06879132 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2024-11-27 | NCT06370819 |
| Sciwind Biosciences USA Co., Ltd. | XW014 | — | COMPLETED | 2024-11-16 | NCT05579314 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Ozempic® | — | COMPLETED | 2024-11-14 | NCT06634927 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 | — | COMPLETED | 2024-10-08 | NCT06435676 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-1780 tablets | — | COMPLETED | 2024-08-13 | NCT06495931 |
| Metabolics Pharma | ENT-03 | — | COMPLETED | 2024-08-12 | NCT05925920 |
| Biomed Industries, Inc. | NA-931 | — | COMPLETED | 2024-08-12 | NCT06615700 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535(D) Tablets | — | COMPLETED | 2024-08-06 | NCT06422039 |
| Eli Lilly | LY3209590 | — | COMPLETED | 2024-07-18 | NCT06169982 |
| Sciwind Biosciences APAC CO Pty. Ltd. | T2026 | — | COMPLETED | 2024-07-13 | NCT05184322 |
| Eli Lilly | LY3938577 | — | COMPLETED | 2024-06-28 | NCT06132126 |
| Kallyope Inc. | K-757 and K-833 QD | — | COMPLETED | 2024-05-15 | NCT06305351 |
| Chong Kun Dang Pharmaceutical | Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG | — | COMPLETED | 2024-04-29 | NCT06483243 |
| Eli Lilly | LY3549492 | — | COMPLETED | 2024-04-22 | NCT05327595 |
| Beijing Dongfang Biotech Co., Ltd. | Exendin-4 Fc fusion protein (JY09) injection | — | COMPLETED | 2024-04-15 | NCT06247748 |
| Eccogene | ECC5004 | — | COMPLETED | 2024-04-15 | NCT06293742 |
| Jiangsu HengRui Medicine Co., Ltd. | HR17031 injection | — | COMPLETED | 2024-04-10 | NCT05292495 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2024-04-02 | NCT05363774 |
| Boryung Pharmaceutical Co., Ltd | BR1019 | — | COMPLETED | 2024-03-31 | NCT06226727 |
| Eccogene | ECC5004 | — | COMPLETED | 2024-03-29 | NCT06268145 |
| Boryung Pharmaceutical Co., Ltd | BR3005 | — | COMPLETED | 2024-03-28 | NCT06289920 |
| Jiangsu HengRui Medicine Co., Ltd. | Acetaminophen/SHR20004 | — | COMPLETED | 2024-03-16 | NCT06137469 |
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Type 2 Diabetes
Novel Type 2 Diabetes Drugs by Company (New molecular entities)
4 companies have an FDA-approved novel drug for Type 2 Diabetes.
Reformulations (34 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
BRYNOVIN
AZURITY
T3 2025
ZITUVIMET XR
ZYDUS LIFESCIENCES
T5 2024
ZITUVIMET
ZYDUS LIFESCIENCES
T5 2023
ZITUVIO
ZYDUS LIFESCIENCES
T2 2023
ATORVALIQ
CMP DEV LLC
T3 2023
KERENDIA
Bayer
T1 2021
TRIJARDY XR
Boehringer Ingelheim
T4 2020
STEGLUJAN
Merck
T4 2017
SEGLUROMET
Merck
T4 2017
OZEMPIC
Novo Nordisk
T1 2017
SYNJARDY XR
Boehringer Ingelheim
T3 2016
INVOKAMET XR
Johnson & Johnson
T4 2016
JENTADUETO XR
Boehringer Ingelheim
T4 2016
BASAGLAR
Eli Lilly
T5 2015
SYNJARDY
Boehringer Ingelheim
T4 2015
GLYXAMBI
Boehringer Ingelheim
T4 2015
XIGDUO XR
AstraZeneca
T4 2014
INVOKAMET
Johnson & Johnson
T4 2014
JARDIANCE
Boehringer Ingelheim
T1 2014
FARXIGA
AstraZeneca
T1 2014
KAZANO
Takeda
T4 2013
KORLYM
CORCEPT THERAP
T5 2012
JANUMET XR
Merck
T3 2012
JENTADUETO
Boehringer Ingelheim
T4 2012
CYCLOSET
VEROSCIENCE
T3 2009
JANUMET
Merck
T4 2007
JANUVIA
Merck
T1 2006
DUETACT
Takeda
T4 2006
CADUET
PHARMACIA
T4 2004
MIFEPREX
DANCO LABS LLC
T1 2000
+4 more
Type 2 Diabetes Drug Targets
Molecular targets of approved and investigational Type 2 Diabetes drugs — 22 targets tracked.
Generic Drugs (12 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
ACARBOSE
STRIDES PHARMA
GLYBURIDE
Teva
LINAGLIPTIN
Teva
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
Dr. Reddy's
LIRAGLUTIDE
BIOCON PHARMA
LYPQOZET
PHARMOBEDIENT
MIFEPRISTONE
Teva
MIGLITOL
ORIENT PHARMA CO LTD
NATEGLINIDE
ZYDUS PHARMS
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
CHARTWELL RX
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
PHARMOBEDIENT
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Sun Pharma
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs